In this study, the XPO1 inhibitors, selinexor and eltanexor, were investigated as anti-cancer agents in five different chordoma patient-derived xenograft (PDX) models, as single agents or in combinations with bortezomib or abemaciclib. The gene discussed is XPO1; the disease is chordoma.